Our Network Soliris recommended for approval in the EU by CHMP for children and adolescents with refractory generalised myasthenia gravis (gMG) Tags: #Rare disease #AstraZeneca Potential approval for Soliris would mark first and only targeted treatment for this patient population in the European Union.
